IP Library › Granted Patent US 7,858,635
Granted Patent B2
US 7,858,635 · App. 11/644,124 · Granted Dec 28, 2010

Spiro compounds as modulators of muscarinic receptors

Assignee: Vertex Pharmaceuticals Incorporated
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,858,635
App. No.
11/644,124
Granted
Dec 28, 2010
Kind
B2
Abstract

The present invention relates to spiro compounds of formula XX as modulators of muscarinic receptors, wherein R 1 , R 2 , R 3 , Z 1 , Z 2 , L, G, n, m, t and p are defined herein. The present invention also provides compositions comprising such modulators, and methods therewith for treating muscarinic receptor mediated diseases.

Claims (136)

1. A compound formula (XX)

or pharmaceutically acceptable salts thereof, wherein

Each of R 1 , R 2 , R 3 is independently Q 1 or Q 2 ;

Z 1 is —N(Q 1 )— or —N(Q 2 );

Z 2 is N;

L is a bond or —CH 2 —;

G is

G 1 is —N—;

G 2 is absent or a C 1-3 alkyl;

G 3 is an aryl or heteroaryl, each optionally substituted with 1-3 substituents independently selected from Q 2 and Q 3 ; and

G 5 is 0 or 1 when G 2 is absent or 0 when G 2 is a C 1-3 alkyl;

Each Q 1 is independently halo, —CN, —NO 2 , —OQ 2 , —S(O) z Q 2 , —S(O) z N(Q 2 ) 2 , —N(Q 2 ) 2 , —C(O)OQ 2 , —C(O)-Q 2 , —C(O)N(Q 2 ) 2 , —C(O)N(Q 2 )(OQ 2 ), —N(Q 2 )C(O)-Q 2 , —N(Q 2 )C(O)N(Q 2 ) 2 , —N(Q 2 )C(O)O-Q 2 , —N(Q 2 )S(O) z -Q 2 or aliphatic optionally including 1-3 substituents independently selected from Q 2 or Q 3 ;

Each Q 2 is independently H, aliphatic, cycloaliphatic, aryl, arylalkyl, heterocyclic, or heteroaryl ring, each optionally including 1-3 substituents independently selected from Q 3 ;

Each Q 3 is halo, oxo, —CN, —NO 2 , —CF 3 , —OCF 3 , —OH, —S(O) z Q 4 , —N(Q 4 ) 2 , —COOQ 4 , —C(O)Q 4 , —OQ 4 , or C 1-4 alkyl optionally substituted with halo, oxo, —CN, —NO 2 , —CF 3 , —OCF 3 , —OH, —SH, —S(O) z H, —NH 2 , or —COOH;

Each Q 4 is aliphatic, cycloaliphatic, aryl, aralkyl, heterocycloaliphatic, heteroaralky, or heteroaryl, each optionally including 1-3 substituents selected from halo, oxo, —CN, —NO 2 , —CF 3 , —OCF 3 , —OH, —SH, —S(O) z H, —NH 2 , or —COOH;

Each Q 5 is a heterocyclic ring optionally including 1-3 substituents selected from halo, C 1-4 alkyl, oxo, —CN, —NO 2 , —CF 3 , —OCF 3 , —OH, —SH, —S(O) z H, —NH 2 , —COOH;

Each i is independently 1, 2, or 3;

Each m and n is independently 2;

Each p is 0 or 1;

Each y is independently 0 or 1;

Each t is 1 to 4; and

Each z is independently 0, 1, or 2.

2. The compound of claim 1 , wherein G 2 is absent.

3. The compound of claim 2 , wherein G 3 is a heteroaryl optionally substituted with 1-3 of halo, cyano, C 1-4 alkoxy, C 1-4 alkyl, cyclopropyl or phenyl optionally substituted with 1-3 of halo, cyano, hydroxy, C 1-4 alkoxy, or C 1-4 alkyl.

4. The compound of claim 2 , wherein G5 is 1.

5. The compound of claim 1 , wherein G is one selected from

6. The compound of claim 1 , wherein Z 1 is —NH—, or —N(Q 1 )-.

7. The compound of claim 6 , wherein Z 1 is —N(Q 1 )- and Q 1 is alkylcarbonylamino, alkylsulfonylamino, alkoxycarbonylamino, aminocarbonyl, alkylcarbonylalkyl, alkoxyalkoxycarbonyl, alkoxyalkyl, alkylaminocarbonyl, alkoxycarbonyl, haloarylcarbonyl, haloarylsulfonyl, alkylheteroarylcarbonyl, heteroarylcarbonyl, heterocycloalkylcarbonyl, haloarylaminocarbonyl, alkylheteroarylsulfonyl, cyanoalkylarylcarbonyl, heterocycloalkoxycarbonyl, alkynyloxycarbonyl, cycloalkoxycarbonyl, heterobicycloarylcarbonyl, alkylheteroarylaminocarbonyl, alkylsulfonyl, alkylcarbonylalkyl, alkoxyarylcarbonyl, haloalkoxycarbonyl, alkylarylcarbonyl, haloalkoxyarylcarbonyl, alkylaminocarbonyl, alkylcarbonyl, or arylaminocarbonyl.

8. The compound of claim 6 , wherein Z 1 is one selected from —NH—,

9. The compound of claim 1 , wherein R 1 is selected from hydrogen, halo, or optionally substituted alkyl, heteroaryl, alkoxy, alkenyl, cycloalkyl, cyanoalkylaryl, alkylaryl, alkylsulfonylaryl, alkylcarbonylaryl, aryl, aminocarbonylaryl, alkylcarbonylaminoaryl, cycloalkenyl, and alkoxyaryl.

10. The compound of claim 9 , wherein R 1 is selected from hydrogen, halo, methyl, —OCH 3

11. The compound of claim 1 , wherein R 2 and R 3 are independently hydrogen or alkyl.

12. The compound of claim 11 , wherein R 2 and R 3 are both hydrogen.

13. The compound of claim 1 , wherein p is 0.

14. The compound of claim 1 , wherein L is a bond.

15. A compound selected from

431

432

433

434

435

436

437

438

439

440

441

442

443

444

445

446

447

448

449

450

451

452

453

454

455

456

457

458

459

460

461

462

463

464

465

466

467

468

469

470

471

472

473

474

475

476

477

478

480

481

482

483

484

485

486

487

488

489

490

491

492

493

494

495

496

497

498

499

500

501

503

504

506

508

509

16. A pharmaceutical composition comprising a compound according to claim 1 and a pharmaceutical carrier.

17. A pharmaceutical composition comprising a compound according to claim 15 and a pharmaceutical carrier.

18. The compound of claim 1 , wherein L is —CH 2 —.

19. A compound formula (XX)

or pharmaceutically acceptable salts thereof, wherein

Each of R 1 , R 2 , R 3 is independently Q 1 or Q 2 ;

Z 1 is —N(Q 1 )- or —N(Q 2 )-;

Z 2 is N;

L is a bond or —CH 2 —;

G is

G 1 is —N—;

G 2 is absent or a C 1-3 alkyl;

G 3 is an aryl or heteroaryl, each optionally substituted with 1-3 substituents independently selected from Q 2 and Q 3 ; and

G5 is 0 or 1 when G 2 is absent or 0 when G 2 is a C 1-3 alkyl;

Each Q 1 is independently halo, —CN, —NO 2 , —OQ 2 , —S(O) z Q 2 , —S(O) z N(Q 2 ) 2 , —N(Q 2 ) 2 , —C(O)OQ 2 , —C(O)-Q 2 , —C(O)N(Q 2 ) 2 , —C(O)N(Q 2 )(OQ 2 ), —N(Q 2 )C(O)-Q 2 , —N(Q 2 )C(O)N(Q 2 ) 2 , —N(Q 2 )C(O)O-Q 2 , —N(Q 2 )S(O) z -Q 2 or aliphatic optionally including 1-3 substituents independently selected from Q 2 or Q 3 ;

Each Q 2 is independently H, aliphatic, cycloaliphatic, aryl, arylalkyl, heterocyclic, or heteroaryl ring, each optionally including 1-3 substituents independently selected from Q 3 ;

Each Q 3 is halo, oxo, —CN, —NO 2 , —CF 3 , —OCF 3 , —OH, —S(O) z Q 4 , —N(Q 4 ) 2 , —COOQ 4 , —C(O)Q 4 , —OQ 4 , or C 1-4 alkyl optionally substituted with halo, oxo, —CN, —NO 2 , —CF 3 , —OCF 3 , —OH, —SH, —S(O) z H, —NH 2 , or —COOH;

Each Q 4 is aliphatic, cycloaliphatic, aryl, aralkyl, heterocycloaliphatic, heteroaralky, or heteroaryl, each optionally including 1-3 substituents selected from halo, oxo, —CN, —NO 2 , —CF 3 , —OCF 3 , —OH, —SH, —S(O) z H, —NH 2 , or —COOH;

Each Q5 is a heterocyclic ring optionally including 1-3 substituents selected from halo, C 1-4 alkyl, oxo, —CN, —NO 2 , —CF 3 , —OCF 3 , —OH, —SH, —S(O) z H, —NH 2 , —COOH;

Each i is independently 1, 2, or 3;

Each m and n is independently 2;

Each p is 1;

Each y is independently 0 or 1;

Each t is 1 to 4; and

Each z is independently 0, 1, or 2.

Assignments (3)
RELEASE OF SECURITY INTEREST Recorded Oct 14, 2016
From: MACQUARIE US TRADING LLC
To: VERTEX PHARMACEUTICALS INCORPORATED; VERTEX PHARMACEUTICALS (SAN DIEGO) LLC
Reel/Frame 040357/0001 →
SECURITY INTEREST Recorded Jul 10, 2014
From: VERTEX PHARMACEUTICALS INCORPORATED; VERTEX PHARMACEUTICALS (SAN DIEGO) LLC
To: MACQUARIE US TRADING LLC
Reel/Frame 033292/0311 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 25, 2007
From: MAKINGS, LEWIS R; BLANCO, MIGUEL GARCIA-GUZMAN; HURLEY, DENNIS J; DRUTU, IOANA; RAFFAI, GABRIEL; BERGERON, DANIELE M; NAKATANI, AKIKO; TERMIN, ANDREAS P; SILINA, ALINA
To: VERTEX PHARMACEUTICALS INCORPORATED
Reel/Frame 019870/0829 →
Continuity (2)
Provisional Application 6075318700 · Dec 22, 2005
Related Publication 20080015179A1 · Jan 17, 2008